Publications by authors named "Rikako Ito"
Background: The quality of life (QOL) of ovarian cancer patients is often impaired by refractory ascites. Cell-free and concentrated ascites reinfusion therapy (CART) is a palliative treatment for refractory ascites, but adverse events, such as fever, are problematic. Several cytokines have been suggested to be responsible for the adverse events, but they have not been investigated in detail.
View Article and Find Full Text PDFArticle Synopsis
- The Proactive Molecular Risk Classifier for Endometrial Cancer identifies four risk groups, but the effectiveness of the lenvatinib/pembrolizumab treatment in relation to this classification is not well understood.
- This study analyzed 20 patients who received this treatment at Iwate Medical University Hospital, assessing their responses and adverse effects over a median follow-up period of 17.8 months.
- Results showed a 60% overall response rate, with the p53 abnormal group experiencing significantly shorter progression-free survival compared to the mismatch repair-deficient group, highlighting the poor prognosis for the p53 abnormal classification despite treatment.
G:C sites distant from 8-oxo-7,8-dihydroguanine (GO, 8-hydroxyguanine) are frequently mutated when the lesion-bearing plasmid DNA is replicated in human cells with reduced Werner syndrome (WRN) protein. To detect the untargeted mutations preferentially, the oxidised guanine base was placed downstream of the reporter supF gene and the plasmid DNA was introduced into WRN-knockdown cells. The total mutant frequency seemed higher in the WRN-knockdown cells as compared to the control cells.
View Article and Find Full Text PDF